Coping with COVID-19

Authors

DOI:

https://doi.org/10.22502/jlmc.v8i1.355

Keywords:

COVID 19

Abstract

Severe acute respiratory syndrome corona virus (SARS-CoV-2) virus made its first appearance in Wuhan, China in December 2019. It has since spread like a wild fire across the globe with over five million corona virus disease (COVID-19) confirmed cases and almost three hundred fifty thousand deaths at the time of writing this article. This could however be only the tip of the iceberg considering the contagious nature of the SARS-CoV-2 virus and the rate at which it is spreading across the globe. China did well to contain the virus with strict lockdown measures, sealing the affected areas, active case finding, tracing, tracking and treating the COVID-19 cases at an astonishing speed. In the absence of specific treatment available as yet, treatment consists of mainly symptomatic management with some experimental medications. Antivirals, specifically Remdesivir has been a strong candidate for the treatment of COVID-19. However, it has yet to receive universal acceptance for the treatment of COVID-19. Chloroquine and Hydroxychloroquine seem to be effective in limiting the replication of SARS-CoV-2 virus in vitro. COVID-19 is highly pandemic in countries where malaria is least prevalent and least pandemic in countries where malaria is highly prevalent. These findings suggest the hypothesis that anti-malarial drugs have efficacy in the treatment of COVID-19.

Downloads

Download data is not yet available.

Author Biography

  • Bhagavat Nepal, Lumbini Medical College and Teaching Hospital

    Editor-in-Chief,

    Professor,

    Department of Ophthalmology

References

Hendaus MA. Remdsivir in the treatment of Corona Virus Disease (COVID-19): A simplified summary. J Biomol Struct Dyn. 2020; [Epub ahead of print] PMID: 32396771 DOI: https://doi.org/10.1080/07391102.2020.1767691

Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615. PMID: 32145386 PMCID: PMC7129391 DOI: https://doi.org/10.1016/j.tmaid.2020.101615

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on efficacy and safety of chloroquine for treatment of COVID-19. J Crit Care. 2020;57: 279-283. PMID: 32173110 DOI: https://doi.org/10.1016/j.jcrc.2020.03.005

Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;28(8):4539-4547. DOI: https://doi.org/10.26355/eurrev_202004_21038

Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in COVID-19. BMJ. 2020;369:m1432. DOI: https://doi.org/10.1136/bmj.m1432

Shitto MO, Afolami OI. Improving efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require Zinc additives-A better synergy for future COVID-19 clinical trails. Infez Med. 2020;28(2):192-197. PMID: 32335560

Schmith VD, Zhou JJ, Lohmer LR. The approved dose of Ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020; [Epub ahead of print]. DOI: https://doi.org/10.1002/cpt.1889

McCartney DM, Byrne DG. Optimization of Vitamin D status for enhanced immune-protection against COVID-19. Ir Med J. 2020;113(4):58. PMID: 32268051

Grant WB, Lahore H, McDonnell SL, Baggerly CA, Fench CB, Aliano JL, et al. Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):E988. DOI: https://doi.org/10.3390/nu12040988

Saghazadeh A, Rezaei N. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Antibodies, Immunoglobulin and Cortcosteroids. Int Immunopharmacol. 2020;84:106560. DOI: https://doi.org/10.1016/j.intimp.2020.106560

Yang L, Tian D, Liu W. Strategies for vaccine development of COVID-19. Sheng Wu Gong Cheng Xue Bao. 2020;36(4):593-604. PMID: 32347054 DOI: https://doi.org/10.13345/j.cjb.200094

Kwok KD, Lai F, Wei WI, Wang SYS, Tang JWT. Herd immunity-Estimating the level required to halt COVID-19 epidemics in affected countries, J Infect. 2020;80(6):e32-e33. PMID: 32209383 PMCID: PMC7151357 DOI: https://doi.org/10.1016/j.jinf.2020.03.027

World Health Organization. Surveillance strategies for COVID-19 human infection: interim guidance, 10 May 2020. World Health Organization, 2020. Available from: https://apps.who.int/iris/handle/10665/332051

Downloads

Published

2020-06-01

Issue

Vol. 8 No. 1 (2020): vol:8, No:1

Section

Editorial

License

  • The Journal of Lumbini Medical College (JLMC) publishes open access articles under the terms of the Creative Commons Attribution (CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  • JLMC requires an exclusive licence to publish the article first in its journal in print and online.
  • The corresponding author should read and agree to the following statement before submission of the manuscript for publication,
    • License agreement
    • In submitting an article to Journal of Lumbini Medical College (JLMC) I certify that:
      1. I am authorized by my co-authors to enter into these arrangements.
      2. I warrant, on behalf of myself and my co-authors, that:
        1. the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
        2. I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JLMC are not in breach of any other obligation;
        3. the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
        4. I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
      3. I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. If the law requires that the article be published in the public domain, I/we will notify JLMC at the time of submission, and in such cases the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication waiver.
      4. I, and all co-authors, agree that, if the article is editorially accepted for publication in JLMC, data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.

                            Please visit Creative Commons web page for details of the terms.

How to Cite

1.
Coping with COVID-19. J Lumbini Med Coll [Internet]. 2020 Jun. 1 [cited 2026 Apr. 17];8(1):1-2. Available from: https://jlmc.edu.np/index.php/JLMC/article/view/355